SPARTA, N.J., May 04, 2020 -- PLx Pharma Inc. (NASDAQ: PLXP) (“PLx” or the “Company”), a late-stage specialty pharmaceutical company focused on developing its clinically.
Protalix BioTherapeutics, Inc. (NYSE American: PLX) (TASE: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant cell-based protein expression system, today announced that it will deliver an oral presentation and three poster presentations on its pegunigalsidase alfa candidate for the treatment of Fabry disease at the 16th Annual WORLDSymposium™ 2020, taking place February 10-13, 2020 at the Hyatt Regency Orlando in Florida.
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
Q4 2019 PLx Pharma Inc Earnings Call
SPARTA, N.J., Feb. 21, 2020 -- PLx Pharma Inc. (NASDAQ: PLXP) (“PLx” or the “Company”), a late-stage specialty pharmaceutical company focused on developing more effective and.
-- Company to begin bioequivalence study of VAZALORE 325 mg dose ---- sNDA submissions expected by year-end -- SPARTA, N.J., May 15, 2020 -- PLx Pharma Inc. (NASDAQ: PLXP).
VAZALORE’S novel mechanism of action with an improved GI safety profile also delivers fast, reliable absorption and predictable antiplatelet effect establishing bioequivalence with regular aspirin. SPARTA, N.J. and PARIS, Sept. 03, 2019 (GLOBE NEWSWIRE) -- PLx Pharma Inc. (PLXP) (“PLx” or the “Company”), a late-stage specialty pharmaceutical company focused on developing more effective and safer products with its patent-protected PLxGuard™ delivery system announced today the presentation of a moderated poster on VAZALORE™ 325 mg at the 2019 European Society of Cardiology (ESC) Congress, the largest global gathering of cardiovascular experts and the simultaneous publication in the Journal of Thrombosis and Thrombolysis.
If you want to know who really controls PLx Pharma Inc. (NASDAQ:PLXP), then you'll have to look at the makeup of its...
SPARTA, N.J., Oct. 28, 2019 -- PLx Pharma Inc. (NASDAQ: PLXP) (“PLx” or the “Company”), a late-stage specialty pharmaceutical company initially focused on developing its.
Q2 2019 PLx Pharma Inc Earnings Call
PLx Pharma (NASDAQ:PLXP) reported Q4 results.Quarterly Results Earnings per share fell 45.16% over the past year to ($0.45), which beat the estimate of ($0.48).Revenue of $23,893 lower by 91.69% from the same period last year, which beat the estimate of $10,000.Conference Call Details Date: Mar 13, 2020Time: 07:05 AM ETView more earnings on PLXPWebcast URL: https://edge.media-server.com/mmc/p/oswfnxddPrice Action 52-week high: $7.4152-week low: $3.25Price action over last quarter: down 5.08%Company Description PLx Pharma Inc is a pharmaceutical company initially focused on developing our clinically-validated and patent-protected PLxGuard delivery system to provide more effective and safer products. The company's PLxGuard delivery system provides more effective and safer aspirin products. The company's lead product candidates are Aspertec 81 mg and 325 mg, which are novel formulations of aspirin that use the PLxGuard delivery system to reduce acute gastrointestinal (GI) side effects while providing antiplatelet effectiveness for cardiovascular disease prevention.See more from Benzinga * Recap: Harvest Capital Credit Q4 Earnings * ReneSola: Q4 Earnings Insights * Recap: Kirkland's Q4 Earnings(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
We often see insiders buying up shares in companies that perform well over the long term. On the other hand, we'd be...
SPARTA, N.J., March 03, 2020 -- PLx Pharma Inc. (NASDAQ: PLXP) (“PLx” or the “Company”), a late-stage specialty pharmaceutical company focused on developing more effective and.
-- PLx Aligning with the FDA on Data Requirements for VAZALORE -- FDA Approves Labeling for 325 mg -- -- Expect to Launch VAZALORE in late 2020 -- SPARTA, N.J., Jan. 06,.
Amid an overall bull market, many stocks that smart money investors were collectively bullish on surged through November 22nd. Among them, Facebook and Microsoft ranked among the top 3 picks and these stocks gained 52% and 49% respectively. Our research shows that most of the stocks that smart money likes historically generate strong risk-adjusted returns. […]
Upon this stockholder approval, on May 15, 2020, the Company completed the $8 million convertible preferred stock financing by investment funds affiliated with Park West Asset Management LLC and MSD Partners, L.P. Please refer to the Company’s Form 8-K, filed with the U.S. Securities and Exchange Commission on March 13, 2020, for a description of the terms of the convertible preferred stock transaction.
SPARTA, N.J., Nov. 08, 2019 -- PLx Pharma Inc. (NASDAQ: PLXP) (“PLx” or the “Company”), a late-stage specialty pharmaceutical company initially focused on developing its.
-- Planning a Bioequivalence Study to Support VAZALORE 325 mg sNDA -- -- Announces $8 Million Convertible Preferred Stock Financing with Park West and MSD Partners -- SPARTA,.
SPARTA, N.J., Jan. 07, 2020 -- PLx Pharma Inc. (NASDAQ: PLXP) (“PLx” or the “Company”), a late-stage specialty pharmaceutical company initially focused on developing its.
Q3 2019 PLx Pharma Inc Earnings Call